2023년 개정된 지침서에 근거한 중등도 이상의 궤양성 대장염 치료의 최신 지견

키워드

참고문헌 (44)

1. 송은미, "Natural history of inflammatory bowel disease: a comparison between the East and the West", Intestinal research, 20(4), pp.418~430 (2022), 대한장연구학회[DOI]
2. 박상형, "Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?", Intestinal research, 20(2), pp.159~164 (2022), 대한장연구학회[DOI]
3. Solberg IC, "Clinical course during the first 10 years of ulcerative colitis : results from a population-based inception cohort(IBSEN Study)", Scand J Gastroenterol, 44, pp.431~440 (2009)
4. 신승용, "Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study", Intestinal research, 20(3), pp.350~360 (2022), 대한장연구학회[DOI]
5. Shiro Nakamura, "Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance", Intestinal research, 20(3), pp.329~341 (2022), 대한장연구학회[DOI]
6. Sandborn WJ, "Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab", Gastroenterology, 137, pp.1250~1260 (2009)
7. 최창환, "궤양성 대장염 치료 가이드라인", Intestinal research, 10(1), pp.1~25 (2012), 대한장연구학회
8. 최창환, "Second Korean guidelines for the management of ulcerative colitis", Intestinal research, 15(1), pp.7~37 (2017), 대한장연구학회
9. Soo-Young Na, "Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease", Gut and Liver, 13(6), pp.604~616 (2019), 거트앤리버 소화기연관학회협의회[DOI]
10. 나수영, "Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis", Intestinal research, 21(1), pp.61~87 (2023), 대한장연구학회[DOI]
11. Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
12. Sands BE, "Ustekinumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 381, pp.1201~1214 (2019)
13. Sandborn WJ, "Tofacitinib as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 376, pp.1723~1736 (2017)
14. Peyrin-Biroulet L, "Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease", Clin Gastroenterol Hepatol, 15, pp.25~36 (2017)[DOI]
15. Guillo L, "Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease : a systematic literature review", J Crohns Colitis, 15, pp.1236~1243 (2021)
16. Sands BE, "Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis", N Engl J Med, 381, pp.1215~1226 (2019)
17. Singh S, "First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis : an updated network meta-analysis", Clin Gastroenterol Hepatol, 18, pp.2179~2191 (2020)
18. Feuerstein JD, "AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis", Gastroenterology, 158, pp.1450~1461 (2020)
19. Panaccione R, "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis", Gastroenterology, 146, pp.392~400 (2014)
20. Mantzaris GJ, "A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis", Am J Gastroenterol, 99, pp.1122~1128 (2004)
21. Singh S, "No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy : pooled analysis of individual participant data from clinical trials", Am J Gastroenterol, 113, pp.1197~1205 (2018)
22. Singh S, "AGA technical review on the management of moderate to severe ulcerative colitis", Gastroenterology, 158, pp.1465~1496 (2020)
23. Ramit Mahajan, "Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study", Intestinal research, 20(1), pp.64~71 (2022), 대한장연구학회[DOI]
24. Toshifumi Hibi, "Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis", Intestinal research, 19(1), pp.53~61 (2021), 대한장연구학회[DOI]
25. Billioud V, "Loss of response and need for adalimumab dose intensification in Crohn's disease : a systematic review", Am J Gastroenterol, 106, pp.674~684 (2011)
26. Rubin DT, "ACG clinical guideline : ulcerative colitis in adults", Am J Gastroenterol, 114, pp.384~413 (2019)
27. Feagan BG, "Sustained clinical remission with vedolizumab in patients with moderate-to-severe ulcerative colitis", Inflamm Bowel Dis, 25, pp.1028~1035 (2019)
28. Motoya S, "Vedolizumab in Japanese patients with ulcerative colitis : a phase 3, randomized, double-blind, placebo-controlled study", PLoS One, 14, pp.e0212989~ (2019)
29. Uzzan M, "Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis : a GETAID cohort", Aliment Pharmacol Ther, 54, pp.312~319 (2021)
30. Ng SC, "Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting", Inflamm Bowel Dis, 24, pp.2431~2441 (2018)
31. Colombel JF, "The safety of vedolizumab for ulcerative colitis and Crohn's disease", Gut, 66, pp.839~851 (2017)
32. Sandborn WJ, "Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy", Aliment Pharmacol Ther, 48, pp.65~77 (2018)
33. Menter A, "Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis : results from the psoriasis longitudinal assessment and registry(PSOLAR)", J Eur Acad Dermatol Venereol, 30, pp.1148~1158 (2016)
34. Papp K, "Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry(PSOLAR)", J Drugs Dermatol, 14, pp.706~714 (2015)
35. Xie W, "Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis : systematic review and meta-analysis of randomised controlled trials", Ann Rheum Dis, 78, pp.1048~1054 (2019)
36. Desai RJ, "Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis : a population-based cohort study", Rheumatology(Oxford), 61, pp.121~130 (2021)
37. "Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis" (2019)[URL]
38. Ytterberg SR, "Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis", N Engl J Med, 386, pp.316~326 (2022)
39. "FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions" (2021)[URL]
40. Danese S, "Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis : results from three phase 3, multicentre, double-blind, randomised trials", Lancet, 399, pp.2113~2128 (2022)
41. Feagan BG, "Filgotinib as induction and maintenance therapy for ulcerative colitis(SELECTION) : a phase 2b", 3 double-blind, randomised, placebo-controlled trial, 2021, pp.397, 2372~2384
42. D'Amico F, "Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis", J Crohns Colitis, 16, pp.835~844 (2022)
43. Reinisch W, "Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases : results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies", Ann Rheum Dis, 82, pp.1049~1058 (2023)
44. Sandborn WJ, "Ozanimod as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 385, pp.1280~1291 (2021)

관련 논문AI추천